Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain

International Journal of Cancer

Volumn 121, Issue 9, 2007, Pages 2031-2041

  Voutsas, Ioannis F ^a   Gritzapis, Angelos D ^a   Mahaira, Louisa G ^a   Salagianni, Maria ^a   Von Hofe, Eric ^b   Kallinteris, Nikoletta L ^a,b   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b Antigen Express Inc   (United States)

Author keywords

Cancer vaccines; CD4+ T cells; HER 2 neu peptides; Ii Key hybrid peptides; MHC class II; Tumor models

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HLA DR4 ANTIGEN; HYBRID PROTEIN; II PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; GENE FREQUENCY; GENE INDUCTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNITY; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SCID MOUSE; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KINETICS; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34648833468     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22936     Document Type: Article

References (56)

1. Van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006;18:98-104.
2. Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 2006;55:85-95.
3. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/new (435-443) cytotoxic T lymphocyte peptide induces effective antitumor immunity against HER-2/neu expressing tumor cells in vivo. Cancer Res 2006;66:5452-60.
4. Chen PW, Ananthaswamy HN. Rejection of K1735 murine melanoma in syngeneic hosts required expression of MHC class I antigens and either class II antigens of IL-2. J Immunol 1993;151:244-50.
5. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474-9.
6. Schoenberger PS, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-5.
7. + T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol 1993;150:4900-6.
8. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-9.
9. Anderson BW, Kudelka AD, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG. Induction of determinant spreading and of TH1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 2000;49:459-66.
10. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. FLt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99:2845-51.
11. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP. Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 1997;17:45-50.
12. Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones. Cancer Immunol Immunother 2002;50:615-22.
13. Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M. Peptide HER-2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001;85:1527-33.
14. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
15. + tumors. Cancer Immunol Immunother 2006;56:601-13.
16. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emans LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:1591-602.
17. Gritzapis AD, Perez SA, Baxevanis CN, Papamichail M. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumor responses in vitro and in vivo. Br J Cancer 2005;92:72-9.
18. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/new+ tumors. Cancer Res 1998;58:4902-8.
19. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu. HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002;8:1014-18.
20. Hueman MT, Stojadivonic A, Storrer CE, Denganzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 2007;56:135-46.
21. Adams S, Humphreys RE. Invariant-chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class-II molecules. Eur J Immunol 1995;25:1693-9.
22. Adams S, Albericio F, Alsina J, Smith ER, Humphreys RE. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class-II molecules. Arzneimittelforschung 1997;47:1069-77.
23. Xu M, Carparo GA, Daibata M, Reyes VE, Humphreys RE. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol 1994;31:723-31.
24. Xu M, Jackson R, Adams S, Humphreys RE. Studies on the activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung 1999;49:791-99.
25. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18:2693-700.
26. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humpreys RE, Murray JL. Ii-Key/HER-2/neu MHC class II-antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004;53:490-6.
27. Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003;21:4128-32.
28. Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-key segment to gp100 (46-58) epitope enhances the production of epitope-specific antibodies. Vaccine 2005;23:2336-8.
29. Kallinteris NL, Wu S, Lu X, Humphreys RE, von Hofe E, Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother 2005;28:352-8.
30. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Proliferative and cytokines responses to class II HER-2/neu-associated peptides in breast cancer. Clin Cancer Res 1998;4:2015-22.
31. Salazar LG, Files J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schifffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-65.
32. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004;22:1916-25.
33. Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K. Vaccination with HER-2/neu DNA or protein subunits protects against the growth of Her-2/neu-expressing murine tumor. Vaccine 2000;19:2598-106.
34. Mittendorf EA, Khoo S, Starrer KA, Harris KA, Jama YH, Dehqanzada ZA, Murray JL, Shriver CD, von Hofe E, Ponniah S, Peoples GE. Early results of a phase I clinical trial of an Ii-key/Her 2neu MHC class II peptide-based vaccine in breast cancer patients. J Clin Oncol 2006;24(Suppl 18):2532(abstract).
35. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 2000;164:3535-42.
36. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-51.
37. Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM, Lichterfeld M, Altfeld M, Frahm N, Rnader C, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific-CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 2004;78:4463-77.
38. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Ervin K, Moes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Apella E, et al. Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999;163:1037-43.
39. Chikamatsu K, Albers A, Stanson J, Kwok WW, Apella E, Whiteside TL, DeLeo AB. P53 (110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+T cells. Cancer Res 2003;63:3675-81.
40. Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-mensah S, Thompson TC, Mitchell MA, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Human Gene Ther 2003;14:763-70.
41. Kim GY, Ko WS, Lee JY, Lee JO, Ryu CH, Choi BT, Park YM, Jeong YK, Lee KJ, Choi KS, Heo MS, Choi YH. Water extract of Cordyceps militaris enhances maturation of murine bone marrow-derived dendritic cells in vitro. Biol Pharm Bull 2006;29:354-60.
42. Klehmet J, Shive C, Guardia-Wolff R, Petersen I, Spack EG, Boehm BO, Weissen R, Forsthuber TG. T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. Clin Immunol 2004;111:53-60.
43. Rojas JM, McArdkle SR, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC. Peptide immunization of HLA-DR-transgenic mice permits the identification of a novel HLA-DR beta 1 *0101- and HLA-Drbeta 1 *0401-restricted epitope from p53. Cancer Immunol Immunother 2005;54:243-53.
44. Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003;9:3260-71.
45. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-6.
46. Bauchereau J, Briere F, Caux C, Davoust J, Leberque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Ann Rev Immunol 2000;18:767-811.
47. Stevanovic S, Schild H. Quantitative aspects of T cell activation-peptide generation and editing by MHC class I molecules. Semin Immunol 1999;11:375-84.
48. Lovitch SB, Pu Z, Unanue ER. Amino terminal flanking residues determine the conformation of a peptide-class II MHC class II complex. J Immunol 2006;176:2958-68.
49. Nelson CA, Fremont DH. Structural principles of MHC class II antigen presentation. Rev Immunogenet 1999;1:47-59.
50. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the anti-tumor immune responses. J Exp Med 1998;188:2357-66.
51. Kirkin AF, Peterson TR, Olsen AC, Li L, thor Straten P, Zeuthen J. Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 1995;41:71-81.
52. Kirkin AF, thor Straten P, Zeuthen J. Differential modulation by interferon-gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother 1996;42:203-12.
53. Kirkin AF, thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vivo immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol Immunother 1999;48:239-46.
54. Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borras-Cuesta F. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur Immunol 2001;31:1780-9.
55. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
56. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004;16:130-6.